Morningside is a venture capital firm based in the greater Boston area, specializing in investments in companies that focus on innovative science and technology. Established in 1986 as a family office for the Chan family, Morningside emphasizes a long-term approach to company-building and maintains a strong commitment to ethical practices. The firm is staffed by a team of experienced investment professionals with expertise in various sectors, including life sciences, digital health, artificial intelligence, materials, and technology. In addition to its investment activities, Morningside is dedicated to philanthropic efforts, supporting education, research, and healthcare initiatives such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.
Geneoscopy develops non-invasive diagnostics using stool-derived eukaryotic RNA to prevent, detect, and guide treatment for gastrointestinal diseases. Its platform technology enables early-stage detection of colorectal cancer neoplasms and improves screening compliance.
Geneoscopy
Series B in 2021
Geneoscopy develops non-invasive diagnostics using stool-derived eukaryotic RNA to prevent, detect, and guide treatment for gastrointestinal diseases. Its platform technology enables early-stage detection of colorectal cancer neoplasms and improves screening compliance.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.